{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:09:18Z","timestamp":1791295758443,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T00:00:00Z","timestamp":1209513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T00:00:00Z","timestamp":1209513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>By inhibiting cyclooxygenase-2, nonsteroidal anti-inflammatory drugs (NSAIDs) decrease aromatase activity and might reduce breast cancer risk by suppressing estrogen synthesis. Epidemiologic evidence for a protective role of NSAIDs in breast cancer, however, is equivocal.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We tested NSAID use for its association with breast cancer incidence in the National Institutes of Health\u2013AARP Diet and Health Study, where 127,383 female AARP (formerly known as the American Association of Retired Persons) members with no history of cancer, aged 51 to 72 years, completed a mailed questionnaire (1996 to 1997). We estimated relative risks of breast cancer for NSAID exposures using multivariate Cox proportional hazards regression models. The state cancer registry and mortality index linkage identified 4,501 primary incident breast cancers through 31 December 2003, including 1,439 estrogen receptor (ER)-positive cancers and 280 ER-negative cancers.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Proportional hazards models revealed no statistically significant association between overall NSAIDs and total breast cancer. As cyclooxygenase inhibition by aspirin (but not other NSAIDs) is irreversible, we tested associations by NSAID type. Although we observed no significant differences in risk for daily use (versus nonuse) of aspirin (relative risk = 0.93, 95% confidence interval = 0.85 to 1.01) or nonaspirin NSAIDS (relative risk = 0.96, 95% confidence interval = 0.87 to 1.05), risk of ER-positive breast cancer was significantly reduced with daily aspirin use (relative risk = 0.84, 95% confidence interval = 0.71 to 0.98) \u2013 a relationship not observed for nonaspirin NSAIDS. Neither aspirin nor nonaspirin NSAIDs were associated with risk of ER-negative breast cancer.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Breast cancer risk was not significantly associated with NSAID use, but daily aspirin use was associated with a modest reduction in ER-positive breast cancer. Our results provide support for further evaluating relationships by NSAID type and breast cancer subtype.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/bcr2089","type":"journal-article","created":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T18:14:29Z","timestamp":1209579269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health\u2013AARP Diet and Health Study"],"prefix":"10.1186","volume":"10","author":[{"given":"Gretchen L","family":"Gierach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James V","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Schatzkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F","family":"Leitzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Richesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert R","family":"Hollenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise A","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,4,30]]},"reference":[{"key":"2053_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2407-6-27","volume":"6","author":"RE Harris","year":"2006","unstructured":"Harris RE, Beebe-Donk J, Alshafie GA: Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2006, 6: 27-10.1186\/1471-2407-6-27.","journal-title":"BMC Cancer"},{"key":"2053_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1471-2407-5-159","volume":"5","author":"E Rahme","year":"2005","unstructured":"Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M: Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005, 5: 159-10.1186\/1471-2407-5-159.","journal-title":"BMC Cancer"},{"key":"2053_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/aje\/kwm216","volume":"166","author":"VA Kirsh","year":"2007","unstructured":"Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B: Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol. 2007, 166: 709-716. 10.1093\/aje\/kwm216.","journal-title":"Am J Epidemiol"},{"key":"2053_CR4","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1054\/bjoc.2000.1709","volume":"84","author":"SA Khuder","year":"2001","unstructured":"Khuder SA, Mutgi AB: Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 2001, 84: 1188-1192. 10.1054\/bjoc.2000.1709.","journal-title":"Br J Cancer"},{"key":"2053_CR5","first-page":"559","volume":"13","author":"RE Harris","year":"2005","unstructured":"Harris RE, Beebe-Donk J, Doss H, Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep. 2005, 13: 559-583.","journal-title":"Oncol Rep"},{"key":"2053_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10552-006-0033-7","volume":"17","author":"C Bosetti","year":"2006","unstructured":"Bosetti C, Gallus S, La Vecchia C: Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control. 2006, 17: 871-888. 10.1007\/s10552-006-0033-7.","journal-title":"Cancer Causes Control"},{"key":"2053_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/pds.1503","volume":"17","author":"S Mangiapane","year":"2008","unstructured":"Mangiapane S, Blettner M, Schlattmann P: Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf. 2008, 17: 115-124. 10.1002\/pds.1503.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2053_CR8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1136\/bmj.299.6710.1247","volume":"299","author":"A Paganini-Hill","year":"1989","unstructured":"Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989, 299: 1247-1250.","journal-title":"BMJ"},{"key":"2053_CR9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/jnci\/88.14.988","volume":"88","author":"KM Egan","year":"1996","unstructured":"Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996, 88: 988-993. 10.1093\/jnci\/88.14.988.","journal-title":"J Natl Cancer Inst"},{"key":"2053_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/sj.bjc.6600760","volume":"88","author":"S Friis","year":"2003","unstructured":"Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH: A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003, 88: 684-688. 10.1038\/sj.bjc.6600760.","journal-title":"Br J Cancer"},{"key":"2053_CR11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/sj.bjc.6600945","volume":"88","author":"HT Sorensen","year":"2003","unstructured":"Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA: Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003, 88: 1687-1692. 10.1038\/sj.bjc.6600945.","journal-title":"Br J Cancer"},{"key":"2053_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/sj.bjc.6602003","volume":"91","author":"LA Garc\u00eda Rodr\u00edguez","year":"2004","unstructured":"Garc\u00eda Rodr\u00edguez LA, Gonz\u00e1lez-P\u00e9rez A: Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer. 2004, 91: 525-529. 10.1038\/sj.bjc.6602003.","journal-title":"Br J Cancer"},{"key":"2053_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1158\/1055-9965.EPI-05-0472","volume":"14","author":"EJ Jacobs","year":"2005","unstructured":"Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, Patel AV, Flanders WD, Calle EE: Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005, 14: 261-264. 10.1158\/1055-9965.EPI-05-0472.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2053_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/jnci\/djk132","volume":"99","author":"EJ Jacobs","year":"2007","unstructured":"Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE: A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007, 99: 608-615. 10.1093\/jnci\/djk132.","journal-title":"J Natl Cancer Inst"},{"key":"2053_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/carcin\/bgl170","volume":"28","author":"U Vogel","year":"2007","unstructured":"Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A: Peroxisome profilerator-activated receptorgamma2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis. 2007, 28: 427-434. 10.1093\/carcin\/bgl170.","journal-title":"Carcinogenesis"},{"key":"2053_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jnci\/dji140","volume":"97","author":"SF Marshall","year":"2005","unstructured":"Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Ziogas A, Ross RK: Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005, 97: 805-812.","journal-title":"J Natl Cancer Inst"},{"key":"2053_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/CEJ.0b013e3282b6fd55","volume":"17","author":"S Friis","year":"2008","unstructured":"Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH: Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev. 2008, 17: 88-96.","journal-title":"Eur J Cancer Prev"},{"key":"2053_CR18","volume-title":"Breast Cancer Res Treat","author":"A Ready","year":"2007","unstructured":"Ready A, Velicer CM, McTiernan A, White E: NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. 2007, DOI 10.1007\/s10549-007-9665-x"},{"key":"2053_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00001648-199403000-00003","volume":"5","author":"DM Schreinemachers","year":"1994","unstructured":"Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994, 5: 138-146. 10.1097\/00001648-199403000-00003.","journal-title":"Epidemiology"},{"key":"2053_CR20","first-page":"71","volume":"6","author":"RE Harris","year":"1999","unstructured":"Harris RE, Kasbari S, Farrar WB: Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999, 6: 71-73.","journal-title":"Oncol Rep"},{"key":"2053_CR21","first-page":"1586","volume":"11","author":"TW Johnson","year":"2002","unstructured":"Johnson TW, Anderson KE, Lazovich D, Folsom AR: Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev. 2002, 11: 1586-1591.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2053_CR22","first-page":"6096","volume":"63","author":"RE Harris","year":"2003","unstructured":"Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A, Women's Health Initiative: Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003, 63: 6096-6101.","journal-title":"Cancer Res"},{"key":"2053_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ijc.22656","volume":"121","author":"L Gallicchio","year":"2007","unstructured":"Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ: Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer. 2007, 121: 211-215. 10.1002\/ijc.22656.","journal-title":"Int J Cancer"},{"key":"2053_CR24","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/aje\/kwm195","volume":"166","author":"JK Gill","year":"2007","unstructured":"Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN: Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol. 2007, 166: 1150-1158. 10.1093\/aje\/kwm195.","journal-title":"Am J Epidemiol"},{"key":"2053_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.294.1.47","volume":"294","author":"NR Cook","year":"2005","unstructured":"Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE: Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005, 294: 47-55. 10.1001\/jama.294.1.47.","journal-title":"JAMA"},{"key":"2053_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","volume":"94","author":"MJ Thun","year":"2002","unstructured":"Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002, 94: 252-266.","journal-title":"J Natl Cancer Inst"},{"key":"2053_CR27","doi-asserted-by":"publisher","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","volume":"126","author":"C Patrono","year":"2004","unstructured":"Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004, 126: 234S-264S. 10.1378\/chest.126.3_suppl.234S.","journal-title":"Chest"},{"key":"2053_CR28","volume-title":"Breast Cancer Res Treat","author":"G Singh-Ranger","year":"2007","unstructured":"Singh-Ranger G, Salhab M, Mokbel K: The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat. 2007, DOI 10.1007\/s10549-007-9641-5"},{"key":"2053_CR29","first-page":"410","volume-title":"Principles of Medical Pharmacology","author":"D Kadar","year":"1998","unstructured":"Kadar D: Anti-inflammatory analgesics. Principles of Medical Pharmacology. Edited by: Kalant H, Roschlau WHE. 1998, New York: Oxford University Press, 410-430."},{"key":"2053_CR30","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1001\/jama.291.20.2433","volume":"291","author":"MB Terry","year":"2004","unstructured":"Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI: association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004, 291: 2433-2440. 10.1001\/jama.291.20.2433.","journal-title":"JAMA"},{"key":"2053_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/aje\/kwi182","volume":"162","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L: Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case\u2013Control Surveillance Study revisited. Am J Epidemiol. 2005, 162: 165-170. 10.1093\/aje\/kwi182.","journal-title":"Am J Epidemiol"},{"key":"2053_CR32","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1023\/B:CACO.0000007973.59863.66","volume":"14","author":"P Moorman","year":"2003","unstructured":"Moorman P, Grubber J, Millikan R, Newman B: Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control. 2003, 14: 915-922. 10.1023\/B:CACO.0000007973.59863.66.","journal-title":"Cancer Causes Control"},{"key":"2053_CR33","first-page":"1213","volume":"10","author":"M Cotterchio","year":"2001","unstructured":"Cotterchio M, Kreiger N, Sloan M, Steingart A: Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2001, 10: 1213-1217.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2053_CR34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/aje\/154.12.1119","volume":"154","author":"A Schatzkin","year":"2001","unstructured":"Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, Hollenbeck AR, Hurwitz PE, Coyle L, Schussler N, Michaud DS, Freedman LS, Brown CC, Midthune D, Kipnis V: Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol. 2001, 154: 1119-1125. 10.1093\/aje\/154.12.1119.","journal-title":"Am J Epidemiol"},{"key":"2053_CR35","doi-asserted-by":"publisher","first-page":"13926","DOI":"10.1073\/pnas.162468699","volume":"99","author":"NV Chandrasekharan","year":"2002","unstructured":"Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic\/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 2002, 99: 13926-13931. 10.1073\/pnas.162468699.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2053_CR36","unstructured":"ICD-O-3 Coding Materials. [http:\/\/seer.cancer.gov\/icd-o-3\/]"},{"key":"2053_CR37","first-page":"70","volume":"32","author":"DS Michaud","year":"2005","unstructured":"Michaud DS, Midthune D, Hermansen S, Leitzmann M, Harlan LC, Kipnis V, Schatzkin A: Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Registry Manage. 2005, 32: 70-75.","journal-title":"J Registry Manage"},{"key":"2053_CR38","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1002\/sim.2098","volume":"23","author":"AC Thi\u00e9baut","year":"2004","unstructured":"Thi\u00e9baut AC, B\u00e9nichou J: Choice of time-scale in Cox's model analysis of epidemiologic cohort data: a simulation study. Stat Med. 2004, 23: 3803-3820. 10.1002\/sim.2098.","journal-title":"Stat Med"},{"key":"2053_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/biomet\/68.3.703","volume":"68","author":"MH Gail","year":"1981","unstructured":"Gail MH, Lubin JH, Rubinstein LV: Likelihood calculations for matched case\u2013control studies and survival studies with tied death times. Biometrika. 1981, 68: 703-707. 10.1093\/biomet\/68.3.703.","journal-title":"Biometrika"},{"key":"2053_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1006\/pmed.1999.0518","volume":"29","author":"PF Coogan","year":"1999","unstructured":"Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S: The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med. 1999, 29: 72-76. 10.1006\/pmed.1999.0518.","journal-title":"Prev Med"},{"key":"2053_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1006\/pmed.1995.1022","volume":"24","author":"RE Harris","year":"1995","unstructured":"Harris RE, Namboodiri K, Stellman SD, Wynder EL: Breast cancer and NSAID use: heterogeneity of effect in a case\u2013control study. Prev Med. 1995, 24: 119-120. 10.1006\/pmed.1995.1022.","journal-title":"Prev Med"},{"key":"2053_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00001648-199603000-00017","volume":"7","author":"RE Harris","year":"1996","unstructured":"Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996, 7: 203-205. 10.1097\/00001648-199603000-00017.","journal-title":"Epidemiology"},{"key":"2053_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1054\/bjoc.2000.1119","volume":"83","author":"CR Sharpe","year":"2000","unstructured":"Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA: Nested case\u2013control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000, 83: 112-120. 10.1054\/bjoc.2000.1119.","journal-title":"Br J Cancer"},{"key":"2053_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000084818","volume":"68","author":"H Swede","year":"2005","unstructured":"Swede H, Mirand AL, Menezes RJ, Moysich KB: Association of regular aspirin use and breast cancer risk. Oncology. 2005, 68: 40-47. 10.1159\/000084818.","journal-title":"Oncology"},{"key":"2053_CR45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/pds.732","volume":"11","author":"GC Curhan","year":"2002","unstructured":"Curhan GC, Bullock AJ, Hankinson SE, Willett WC, Speizer FE, Stampfer MJ: Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women. Pharmacoepidemiol Drug Saf. 2002, 11: 687-693. 10.1002\/pds.732.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2053_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/pds.755","volume":"12","author":"R Paulose-Ram","year":"2003","unstructured":"Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y: Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf. 2003, 12: 315-326. 10.1002\/pds.755.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2053_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.anndiagpath.2006.03.002","volume":"10","author":"C Leo","year":"2006","unstructured":"Leo C, Faber S, Hentschel B, H\u00f6ckel M, Horn LC: The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol. 2006, 10: 327-332. 10.1016\/j.anndiagpath.2006.03.002.","journal-title":"Ann Diagn Pathol"},{"key":"2053_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/bcr1678","volume":"9","author":"LR Howe","year":"2007","unstructured":"Howe LR: Inflammation and breast cancer. Cyclooxygenase\/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007, 9: 210-10.1186\/bcr1678.","journal-title":"Breast Cancer Res"},{"key":"2053_CR49","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/jnci\/dji306","volume":"97","author":"ST Mayne","year":"2005","unstructured":"Mayne ST, Lippman SM: Cigarettes: a smoking gun in cancer chemoprevention. J Natl Cancer Inst. 2005, 97: 1319-1321.","journal-title":"J Natl Cancer Inst"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr2089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/bcr2089\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr2089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:08:27Z","timestamp":1728385707000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr2089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,30]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,4]]}},"alternative-id":["2053"],"URL":"https:\/\/doi.org\/10.1186\/bcr2089","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,30]]},"assertion":[{"value":"17 December 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R38"}}